RMD — ResMed Inc.

ResMed Inc. Q3 Fiscal Year 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $1.43 billion, an 11% increase year-over-year (8% growth on a constant currency basis).
• Gross Margin: 62.8%, up 290 basis points year-over-year and 50 basis points sequentially.
• Operating Income: Increased by 18%, with an operating margin of 36.7%.
• Non-GAAP Earnings Per Share (EPS): Increased by 21%, with a net income growth of 20%.
• Free Cash Flow: $520 million, maintaining over 100% free cash flow conversion.
• Shareholder Returns: $262 million returned through dividends and share repurchases, with a quarterly dividend of $0.60 per share.

2. Strategic Updates and Business Highlights:

• Leadership Transition: Brett Sandercock announced his retirement, with Aaron Blumer appointed as the new CFO.
• Product Innovation: Continued rollout of new fabric-based masks (AirTouch N30i, F30i Comfort, F30i Clear) showing strong early adoption and positive feedback.
• Acquisition: Agreement to acquire Noctrix Health for $340 million, expected to close on June 1, 2026. Noctrix's product, NIDRA, treats restless leg syndrome and is anticipated to enhance ResMed's market position.
• Global Strategy: Focus on expanding the digital health ecosystem, particularly in sleep health and breathing health, with tailored approaches for different markets (e.g., China).
• CME Programs: Over 80,000 courses completed, leading to increased engagement from primary care physicians in sleep health.

3. Forward Guidance and Outlook:

• Long-term Growth Expectations: Anticipate high single-digit revenue growth and earnings growth outpacing revenue growth through 2030.
• Gross Margin Outlook: Expected to remain between 62% and 63% for fiscal year 2026.
• Investment Plans: Continued focus on R&D and strategic acquisitions, with an emphasis on enhancing digital health capabilities.

4. Bad News, Challenges, or Points of Concern:

• Component Cost Pressures: While gross margins improved, there are concerns about potential cost inflation due to geopolitical issues and supply chain challenges.
• Market Competition: Competitive pressures in the device segment remain, with new entrants and technologies challenging ResMed's market position.
• Reimbursement Risks: Questions raised regarding the reimbursement landscape, particularly with changes in funding models affecting DME customers.
• Weather Impact: Some analysts noted potential weather-related impacts on device sales, although management did not confirm significant effects.

5. Notable Q&A Insights:

• Component Costs: Management acknowledged ongoing geopolitical uncertainties affecting fuel costs but expressed confidence in their supply chain resilience and ability to maintain gross margin improvements.
• Noctrix Acquisition: The acquisition is expected to enhance growth and profitability, with ResMed's established market access likely to accelerate Noctrix's revenue.
• U.S. Device Market: Management reported solid growth despite concerns about competitive launches and market share shifts, emphasizing their proactive approach to innovation.
• Primary Care Engagement: The CME programs are successfully increasing referral volumes among engaged PCPs, contributing to higher diagnosis and treatment rates for sleep apnea.

Overall, ResMed Inc. reported strong financial results in Q3 2026, driven by product innovation and strategic growth initiatives, while navigating challenges in component costs and competitive pressures. The company remains optimistic about its long-term growth trajectory and market position.